2-{2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]ethyl}-1H-isoindole-1,3(2H)-dione | 868994-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-{2-[(9-fluoro-7-oxo-6,7-dihydro-3H-benzo[h]imidazo[4,5-f]isoquinolin-2-yl)thio]ethyl}-1H-isoindole-1,3(2H)-dione
• 英文别名: 2-[2-[(15-Fluoro-11-oxo-3,5,10-triazatetracyclo[11.4.0.02,6.07,12]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-4-yl)sulfanyl]ethyl]isoindole-1,3-dione
• CAS: 868994-03-0
• 化学式: C₂₄H₁₅FN₄O₃S
• 分子量: 458.473
• InChiKey: LDVVXQBPKUDDHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
  申请人：Incyte Holdings Corporation

  公开号：EP3042655A1

  公开（公告）日：2016-07-13

  Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.

  提供了治疗干眼症和其他相关眼部疾病的方法、试剂盒和组合物，其中所述方法、试剂盒和组合物利用JAK抑制剂。
• Tetracyclic inhibitors of Janus kinases
  申请人：Rodgers D. James

  公开号：US20060106020A1

  公开（公告）日：2006-05-18

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

  本发明提供了一种调节Janus激酶活性的化合物，可用于治疗与Janus激酶活性相关的疾病，例如免疫相关疾病和癌症。
• TETRACYCLIC INHIBITORS OF JANUS KINASES
  申请人：Rodgers James D.

  公开号：US20090215766A1

  公开（公告）日：2009-08-27

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

  本发明提供了一种可以调节Janus激酶活性的化合物，这些化合物可用于治疗与Janus激酶活性相关的疾病，例如免疫相关疾病和癌症。
• METHOD OF TREATING MUSCULAR DEGRADATION
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20130310340A1

  公开（公告）日：2013-11-21

  A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such as may result from ventilation.